PROGRAM
All Times are ET
Program is subject to change
Saturday, February 6, 2027
| 7:55 am | Welcome and Overview / Pre-Program Test Philip J. Rosenfeld, Omer Trivizki |
| Session I: AMD Imaging and Early to Intermediate Progression Moderators: Philip Rosenfeld, Giovanni Gregori, Omer Trivizki Panelists: Christine Curcio, Amitha Domalpally, James Fujimoto, Karl Csaky, Michael Ip, Pearse Keane, Marc Steffen Schmitz-Valckenberg, Maximillian Pfau |
|
| 8:00 | Macular Xanthophyll Carotenoids and AMD Progression Risk Over Three Years in ALSTAR2 Christine A. Curcio |
| 8:10 | Natural History of Retinal Layer Changes in Intermediate AMD Amitha Domalpally |
| 8:20 | High Resolution OCT Outer Retinal Biomarkers in AMD James Fujimoto |
| 8:30 | Update on Assessing Cones at Risk in Dry AMD: Functional Significances Karl Csaky |
| 8:40 | Baseline OCT Imaging Biomarkers as Predictors of Progression from Intermediate AMD to Neovascular AMD and Visual Decline Michael Ip |
| 8:50 | Drusen and Atrophy Dynamics in the Transition from Early to Late Non-Neovascular AMD Pearse Keane |
| 9:00 | Structure-Function Correlations in Early Atrophic AMD Marc Steffen Schmitz-Valckenberg |
| 9:10 | Parafoveal Dark Adaptation in the EVITE-AMD Study: The Earliest Functional Biomarker of AMD Maximillian Pfau |
| Session II: Progression of Geographic Atrophy Moderators: Omer Trivizki, Zohar Yehoshua, Philip Rosenfeld Panelists: Giuseppe Querques, Seung-Young Yu, Enrico Borrelli, Philip J. Rosenfeld, Omar Badla, Aaron Lee, Roy Schwartz, Ruikang Wang |
|
| 9:20 | Pathogenic Role of Individual Structural Lesions in the Progression of Geographic Atrophy Giuseppe Querques |
| 9:30 | Morphologic and Topographic Phenotypes of Geographic Atrophy in a Korean Cohort: Longitudinal Progression and Visual Outcomes Seung-Young Yu |
| 9:40 | Macular Atrophy in Neovascular AMD vs. Geographic Atrophy: Similarities and Differences Enrico Borrelli |
| 9:50 | What Distinguishes Fast from Slow Progressors of Atrophy in AMD Philip J. Rosenfeld or Omar Badla |
| 10:00 | Using Deep Learning for Geographic Atrophy Trajectories Aaron Lee |
| 10:10 | OCTFNet: A New Deep Learning Architecture for Mapping Retinal Function from OCT in Geographic Atrophy Roy Schwartz |
| 10:20 | Device-agnostic Automated Segmentation of Hyper-TDs Associated with GA Using Deep-learning Driven OCT Framework Ruikang Wang |
Session III: Perfusion and AMD Moderators: Philip J. Rosenfeld, Da Meng, Nancy Holekamp Panelists: Randy Kardon, Edward Linton, Mario Saravia, Omer Trivizki, Nadia Waheed |
| 10:30 | Introduction to Laser Speckle Flowgraphy (LSFG) and its Clinical Applications Randy Kardon |
| 10:40 | Laser Speckle Flowgraphy to Evaluate Retinal and Choroidal Perfusion in Non-exudative AMD Edward Linton |
| 10:50 | Assessment of Choroidal Circulation with ICG+AI: Old Dog, New Trick Mario Saravia |
| 11:00 | The Role of Choroidal Perfusion in the Progression of AMD Omer Trivizki |
| 11:10 | Choriocapillaris and Retinal Hemodynamic Changes in Normative Aging and AMD Nadia Waheed |
| 11:20 | Inhibition of the Endothelin-A (ETₐ) Receptor for the Treatment of Perfusion-Related Ocular Diseases TBD |
| 11:30 | Case Presentation and Discussion All Speakers |
| Session IV: Clinical Trial Designs and Endpoints Moderators: Philip Rosenfeld, Giovanni Gregori, Jaclyn Kovach Panelists: Yi Zhang, David Lally, Sara Beqiri, Gissel Herrera, Alessandro Berni, Zhichao Wu, SriniVas Sadda, Glenn Jaffe |
|
| 12:00 pm | Cross-Device Field-of-View Scale Differences in Clinical OCT Angiography: Phantom Calibration and Large-Scale Clinical Validation Yi Zhang |
| 12:10 | Test-retest Reliability of ETDRS BCVA and LLVA in GA Clinical Trials David Lally |
| 12:20 | Paired-Eye Clinical Trials Using Subjects with Bilateral GA Sara Beqiri |
| 12:30 | How Well Do Prior GA Growth Rates Predict Future GA Growth Rates? Gissel Herrera |
| 12:40 | Recommended Microperimetry Grid Patterns in Eyes with Intermediate AMD Alessandro Berni |
| 12:50 | Microperimetry Endpoints for Non-Neovascular AMD Treatment Trials Zhichao Wu |
| 1:00 | GA Severity Score: A Functionally-relevant Approach for Describing Atrophy Progression SriniVas Sadda |
| 1:10 | A novel AI Progression Model Algorithm to Measure GA Recreates Phase 3 Clinical Trial Results Glenn Jaffe |
| Session V: Non-Exudative AMD Pipeline: Emerging and Late-Stage Therapies Moderators: Nicolas Yannuzzi, Omer Trivizki, Maura DiNicola Panelists: Jay Berdia, Fuad Makkouk, Jayakrishna Ambati, Emily Chew, Philip J. Rosenfeld, Veeral Sheth, Quan Dong Nguyen, Roger Goldberg, Charles Wykoff, Jeffrey Heier |
|
| 1:20 | CTX114 for Intermediate AMD: Phase 1 Single Ascending Dose Results Jay Berdia |
| 1:30 | CTX114 in Geographic Atrophy Secondary to Age-related Macular Degeneration: Phase 1 Results Fuad Makkouk |
| 1:40 | Dual Inflammasome Inhibition for Geographic Atrophy Jayakrishna Ambati |
| 1:50 | New Oral AMD Supplement, Beyond AREDS2 Emily Chew |
| 2:00 | Oral Tonabersat Therapy for the Treatment of Intermediate AMD Philip J. Rosenfeld |
| 2:10 | Phase 1/2 Study of Single-Dose Intravitreal SAR446597, Dual Complement Inhibitor Gene Therapy for Geographic Atrophy: Updated Data from Escalation Cohort Veeral Sheth |
| 2:20 | Suprachoroidal Gene Therapy: KRIYA-825, A New Approach to Complement Inhibition in Geographic Atrophy Quan Dong Nguyen |
| 2:30 | Safety Results for Vonaprument in Patients with Geographic Atrophy from the Phase 3 ARCHER II Trial Roger Goldberg |
| 2:40 | Efficacy of Vonaprument in Patients with Geographic Atrophy: Results from the Phase 3 ARCHER II Trial Charles Wykoff |
| 2:50 | The Path to a New Cell-Based Therapy for Advanced Geographic Atrophy Jeffrey Heier |
| Session VI: Approved Therapies for Non-Exudative AMD Moderators: Harry Flynn, Da Meng, Brian Goldhagen Panelists: Lawrence Singerman, David Brown, Eleonora Lad, Diana Do |
|
| 3:00 | 5 Years of Pegcetacoplan in Geographic Atrophy Secondary to AMD: Insights from the Clinical Program and the Role of Artificial Intelligence Lawrence Singerman |
| 3:10 | Anti-Complement Induced Changes to the Retinal Nerve Fiber Layer David Brown |
| 3:20 | Current Estimates of the Treatment Burden, Treatment Patterns, and Clinical Outcomes in Patients with Dry ARMD with GA in the United States Eleonora Lad |
| 3:30 | Update on Photobiomodulation for AMD Diana Do |
| Session VII: Imaging, Functional Testing & Early-Phase Pipeline in Exudative AMD Moderators: Raquel Goldhardt, Luis Haddock, Philip Rosenfeld Panelists: David Sarraf, Usha Chakravarthy, Monika Fleckenstein, Sobha Sivaprasad, David Boyer, Xiaodong Sun, Linda Tong, Baruch D. Kuppermann, Lejla Vajzovic |
|
| 3:40 | A New Early OCT Biomarker of Neovascular Activity in AMD David Sarraf |
| 3:50 | Role of en face Imaging in the Assessment of Structural Integrity of the Outer Retina in Treated nAMD Usha Chakravarthy |
| 4:00 | Longitudinal Changes in Retinal Sensitivity Associated with Type 1 MNV Monika Fleckenstein |
| 4:10 | Reliability of Detecting Fibrosis and its Functional Decline Sobha Sivaprasad |
| 4:20 | First-in-Human Safety and Early Efficacy Outcomes of OCUL101, a Novel Dual VEGF and Complement C5 Trap, Demonstrating Promising Results Relative to Aflibercept in Neovascular Age-Related Macular Degeneration David Boyer |
| 4:30 | First-in-Human Phase I Results for QBR202: A Bispecific Molecule Targeting VEGF and Ang-2 with new Molecular Engineering enhancing Long Intraocular Retention Xiaodong Sun |
| 4:40 | Two-year Clinical Results of Subretinal AAV2-VEGF Gene Therapy (LX102) for Neovascular AMD Linda Tong |
| 4:50 | 2-Year Follow-Up: PRISM Phase 2b Clinical Trial Evaluating Investigational 4D-150, an Intravitreal Gene Therapy, in a Broad Neovascular AMD Population Baruch D. Kuppermann |
| 5:00 | ASCENT One-Year Primary Endpoint: Results from the Phase 3 Pivotal Trial of Sura-vec Gene Therapy for Neovascular AMD Lejla Vajzovic |
| Session VIII: Late-Phase & Pivotal Trials in Neovascular AMD Moderators: Ninel Gregori, Philip Rosenfeld, Omer Trivizki Panelists: Robyn Guymer, Mark Barakat, Allen Ho, Arshad Khanani, Szilárd Kiss, David Eichenbaum, Carl Regillo, Rishi Singh, Dilsher Dhoot, Dante Pieramici |
|
| 5:10 | VOYAGER Study 12-Month Results: Clinical Outcomes, Imaging Biomarkers, and PCV Cohort Findings in nAMD Robyn Guymer |
| 5:20 | Subretinal Delivery of Investigational Sura-vec Gene Therapy for Neovascular Age-related Macular Degeneration: 5-year Long-term Follow-up of Phase 1/2a Participants Mark Barakat |
| 5:30 | One-year Safety Outcomes from ATMOSPHERE and ASCENT: The Global Pivotal Program Evaluating Sura-vec Gene Therapy for Neovascular AMD Allen Ho |
| 5:40 | ATMOSPHERE One-Year Primary Endpoint: Results from the Phase 2b/3 Pivotal Trial of Sura-vec Gene Therapy for Neovascular AMD Arshad Khanani |
| 5:50 | Ixoberogene Soroparvovec (Ixo-vec) for Long-Term Treatment of Neovascular Age-Related Macular Degeneration (nAMD) Szilárd Kiss |
| 6:00 | Topline Results from the LUCIA Phase 3 Trial of Bioerodible EYP-1901 (vorolanib intravitreal insert) vs Aflibercept in Patients with Wet Age-Related Macular Degeneration David Eichenbaum |
| 6:10 | LUGANO Phase 3 Trial of Bioerodible EYP-1901 (vorolanib intravitreal insert) vs Aflibercept in Patients with Wet Age-Related Macular Degeneration: Subgroup Analysis Carl Regillo |
| 6:20 | Topline Results from the LUGANO Phase 3 Trial of Bioerodible EYP-1901 (vorolanib intravitreal insert) vs Aflibercept in Patients with Wet Age-Related Macular Degeneration Rishi Singh |
| 6:30 | SOL: Evolving Clinical Evidence and New Insights Dilsher Dhoot |
| 6:40 | Comparing Safety Across nAMD Gene-Therapy Programs: Inflammation, Pigmentary Changes, and Lessons in Prophylaxis Dante Pieramici |
| Session IX: Update on Clinical Therapies for Exudative AMD Moderators: Da Meng, Philip Rosenfeld, Omer Trivizki Panelists: Gemmy Cheung Chui Ming, Arshad Khanani, Andrew Moshfeghi, Anat Loewenstein, Saad Ahmad, Sunir Garg, Clare Bailey |
|
| 6:50 | Faricimab for Polypoidal Choroidal Vasculopathy: Two-year Results from the SALWEEN Trial Gemmy Cheung Chui Ming |
| 7:00 | Efficacy, Safety, and Durability of Faricimab Dosing up to Q24W in Patients With nAMD: Week 28 Results from the Phase 3b/4 CONSTANCE Trial Arshad Khanani |
| 7:10 | Real-World Anti-VEGF Treatment Utilization and Long-Term Outcomes in Neovascular Age-Related Macular Degeneration: Analyses of the Vestrum Health Retinal Database® & AAO IRIS® Registry Andrew Moshfeghi |
| 7:20 | Rethinking Periodic Recurrence in AMD: Home OCT Insights Anat Loewenstein |
| 7:30 | Port Delivery Platform with Ranibizumab (PDS): Real-world Intervals, Safety, Treatment Patterns, and Outcomes (SUVISTA Study) Saad Ahmad |
| 7:40 | Aflibercept 8 mg in Previously Treated Patients With nAMD: 48-Week Outcomes from the Phase 3b ELARA Trial Sunir Garg |
| 7:50 | Effectiveness and Safety of Aflibercept 8 mg in Patients With nAMD: Findings From SPECTRUM, the First Global Real-World Study Clare Bailey |
| 8:00 | Closing Remark |